Altera ( ALTR) upgraded at Goldman to Neutral from Conviction Sell as the stock has already priced in its negative fundamental outlook. Opportunities cited are improved full cycle earnings power from continued OpEx discipline and a recovery in the industrial end market. Increased target price to $16 from $12. Estimates for 2009 were also raised to 62 cents from 58 cents and 2010 estimates were raised to 85 cents from 65 cents.

Alcatel-Lucent ( ALU) upgraded at Merrill/BofA to Buy. Analyst said ALU is oversold, down 20% from recent peak, and balance sheet risk will fade. Maintains $2.80 price target and 2009 EPS estimate at -31 cents.

Bristol-Myers ( BMY) rated new Overweight at Morgan Stanley. $22 price target. Expect encouraging news on potential blockbusters.

Coca-Cola Enterprises ( CCE) upgraded at Credit Suisse to Outperform from Neutral. The increase in ratings was prompted by better structural visibility and the expectation for improvements in its fundamentals. Increased its target price to $20 from $12.

Cisco Systems ( CSCO) rated new Buy at Citigroup. $23 price target. Company should benefit from an economic recovery and increase in network spending.

Foot Locker ( FL) initiated at UBS. Initiated with a Neutral rating and $10 price target. Introduces fiscal 2010 EPS estimates of 73 cents.

Forest Labs ( FRX) rated new Overweight at Morgan Stanley. $31 price target. Expect Savella to generate material upside.

Goldman Sachs ( GS) numbers lifted at Merrill/BofA to $180 from $175. 2009 EPS estimate increased to $19.21 and 2010 EPS estimate raised to $20.83 from $19.78.

If you liked this article you might like

7 Essential Rules for Investing in Tech Stocks

Hewlett Packard Enterprise Becomes the Latest Tech Titan to Slash Jobs

Your Guide to Making a Lot of Money on the Driverless Car Boom

Buying Nvidia Now Is Like Getting Intel Way Back in 1993, Jim Cramer Says

Google's Waymo Teams With Intel on Self Driving Technology